PMC:7408073 / 100000-100961 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T1","span":{"begin":124,"end":139},"obj":"Body_part"},{"id":"T2","span":{"begin":168,"end":173},"obj":"Body_part"},{"id":"T3","span":{"begin":629,"end":634},"obj":"Body_part"},{"id":"T4","span":{"begin":685,"end":693},"obj":"Body_part"},{"id":"T5","span":{"begin":829,"end":837},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma317863"},{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma7199"},{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma9670"},{"id":"A4","pred":"fma_id","subj":"T4","obj":"http://purl.org/sig/ont/fma/fma85272"},{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma85272"}],"text":"In humans ORE1001/GL1001/MLN-4760 was already proposed and tested in clinical trials. Its pharmaceutical indication was for digestive tract inflammations (Inflammatory bowel disease, gastritis and colitis) that are correlated with overexpression of ACE2. In a Phase I clinical testing up 14 days dosing, ORE1001 was well tolerated. Subjects received drug (dosing up to 2100 mg) with no side adverse effects reported. In particular, 47 subjects received single-dose from 2.1 to 2100 mg and 24 subjects received 14 day multiple doses from 50 mg to 1800 mg. All doses were well tolerated, with no significant side effects including blood pressure. Pharmacokinetics of orally administered capsules was consistent with once-daily dosing. (http://oreholdings.com/wp-content/uploads/2013/06/09.10.09-425.pdf). 300 mg (active drug) oral capsules were used in a Phase Ib/IIa clinical trial that was, however, abandoned. (https://clinicaltrials.gov/ct2/show/NCT01039597)."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T195","span":{"begin":124,"end":139},"obj":"Body_part"},{"id":"T196","span":{"begin":629,"end":634},"obj":"Body_part"}],"attributes":[{"id":"A195","pred":"uberon_id","subj":"T195","obj":"http://purl.obolibrary.org/obo/UBERON_0001555"},{"id":"A196","pred":"uberon_id","subj":"T196","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"}],"text":"In humans ORE1001/GL1001/MLN-4760 was already proposed and tested in clinical trials. Its pharmaceutical indication was for digestive tract inflammations (Inflammatory bowel disease, gastritis and colitis) that are correlated with overexpression of ACE2. In a Phase I clinical testing up 14 days dosing, ORE1001 was well tolerated. Subjects received drug (dosing up to 2100 mg) with no side adverse effects reported. In particular, 47 subjects received single-dose from 2.1 to 2100 mg and 24 subjects received 14 day multiple doses from 50 mg to 1800 mg. All doses were well tolerated, with no significant side effects including blood pressure. Pharmacokinetics of orally administered capsules was consistent with once-daily dosing. (http://oreholdings.com/wp-content/uploads/2013/06/09.10.09-425.pdf). 300 mg (active drug) oral capsules were used in a Phase Ib/IIa clinical trial that was, however, abandoned. (https://clinicaltrials.gov/ct2/show/NCT01039597)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"3477","span":{"begin":249,"end":253},"obj":"Gene"},{"id":"3478","span":{"begin":25,"end":28},"obj":"Gene"},{"id":"3479","span":{"begin":3,"end":9},"obj":"Species"},{"id":"3480","span":{"begin":155,"end":181},"obj":"Disease"},{"id":"3481","span":{"begin":183,"end":204},"obj":"Disease"}],"attributes":[{"id":"A3477","pred":"tao:has_database_id","subj":"3477","obj":"Gene:59272"},{"id":"A3478","pred":"tao:has_database_id","subj":"3478","obj":"Gene:4295"},{"id":"A3479","pred":"tao:has_database_id","subj":"3479","obj":"Tax:9606"},{"id":"A3480","pred":"tao:has_database_id","subj":"3480","obj":"MESH:D015212"},{"id":"A3481","pred":"tao:has_database_id","subj":"3481","obj":"MESH:D005756"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"In humans ORE1001/GL1001/MLN-4760 was already proposed and tested in clinical trials. Its pharmaceutical indication was for digestive tract inflammations (Inflammatory bowel disease, gastritis and colitis) that are correlated with overexpression of ACE2. In a Phase I clinical testing up 14 days dosing, ORE1001 was well tolerated. Subjects received drug (dosing up to 2100 mg) with no side adverse effects reported. In particular, 47 subjects received single-dose from 2.1 to 2100 mg and 24 subjects received 14 day multiple doses from 50 mg to 1800 mg. All doses were well tolerated, with no significant side effects including blood pressure. Pharmacokinetics of orally administered capsules was consistent with once-daily dosing. (http://oreholdings.com/wp-content/uploads/2013/06/09.10.09-425.pdf). 300 mg (active drug) oral capsules were used in a Phase Ib/IIa clinical trial that was, however, abandoned. (https://clinicaltrials.gov/ct2/show/NCT01039597)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T555","span":{"begin":140,"end":153},"obj":"Disease"},{"id":"T556","span":{"begin":155,"end":181},"obj":"Disease"},{"id":"T557","span":{"begin":183,"end":192},"obj":"Disease"},{"id":"T558","span":{"begin":197,"end":204},"obj":"Disease"}],"attributes":[{"id":"A555","pred":"mondo_id","subj":"T555","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"},{"id":"A556","pred":"mondo_id","subj":"T556","obj":"http://purl.obolibrary.org/obo/MONDO_0005265"},{"id":"A557","pred":"mondo_id","subj":"T557","obj":"http://purl.obolibrary.org/obo/MONDO_0004966"},{"id":"A558","pred":"mondo_id","subj":"T558","obj":"http://purl.obolibrary.org/obo/MONDO_0005292"}],"text":"In humans ORE1001/GL1001/MLN-4760 was already proposed and tested in clinical trials. Its pharmaceutical indication was for digestive tract inflammations (Inflammatory bowel disease, gastritis and colitis) that are correlated with overexpression of ACE2. In a Phase I clinical testing up 14 days dosing, ORE1001 was well tolerated. Subjects received drug (dosing up to 2100 mg) with no side adverse effects reported. In particular, 47 subjects received single-dose from 2.1 to 2100 mg and 24 subjects received 14 day multiple doses from 50 mg to 1800 mg. All doses were well tolerated, with no significant side effects including blood pressure. Pharmacokinetics of orally administered capsules was consistent with once-daily dosing. (http://oreholdings.com/wp-content/uploads/2013/06/09.10.09-425.pdf). 300 mg (active drug) oral capsules were used in a Phase Ib/IIa clinical trial that was, however, abandoned. (https://clinicaltrials.gov/ct2/show/NCT01039597)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1","span":{"begin":3,"end":9},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T2","span":{"begin":59,"end":65},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T3","span":{"begin":124,"end":139},"obj":"http://purl.obolibrary.org/obo/UBERON_0001555"},{"id":"T4","span":{"begin":258,"end":259},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T5","span":{"begin":277,"end":284},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T6","span":{"begin":629,"end":634},"obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"T7","span":{"begin":629,"end":634},"obj":"http://www.ebi.ac.uk/efo/EFO_0000296"},{"id":"T8","span":{"begin":811,"end":817},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T9","span":{"begin":851,"end":852},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"In humans ORE1001/GL1001/MLN-4760 was already proposed and tested in clinical trials. Its pharmaceutical indication was for digestive tract inflammations (Inflammatory bowel disease, gastritis and colitis) that are correlated with overexpression of ACE2. In a Phase I clinical testing up 14 days dosing, ORE1001 was well tolerated. Subjects received drug (dosing up to 2100 mg) with no side adverse effects reported. In particular, 47 subjects received single-dose from 2.1 to 2100 mg and 24 subjects received 14 day multiple doses from 50 mg to 1800 mg. All doses were well tolerated, with no significant side effects including blood pressure. Pharmacokinetics of orally administered capsules was consistent with once-daily dosing. (http://oreholdings.com/wp-content/uploads/2013/06/09.10.09-425.pdf). 300 mg (active drug) oral capsules were used in a Phase Ib/IIa clinical trial that was, however, abandoned. (https://clinicaltrials.gov/ct2/show/NCT01039597)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T3495","span":{"begin":90,"end":104},"obj":"Chemical"},{"id":"T11","span":{"begin":350,"end":354},"obj":"Chemical"},{"id":"T72202","span":{"begin":818,"end":822},"obj":"Chemical"}],"attributes":[{"id":"A91673","pred":"chebi_id","subj":"T3495","obj":"http://purl.obolibrary.org/obo/CHEBI_52217"},{"id":"A64767","pred":"chebi_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A87794","pred":"chebi_id","subj":"T72202","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":"In humans ORE1001/GL1001/MLN-4760 was already proposed and tested in clinical trials. Its pharmaceutical indication was for digestive tract inflammations (Inflammatory bowel disease, gastritis and colitis) that are correlated with overexpression of ACE2. In a Phase I clinical testing up 14 days dosing, ORE1001 was well tolerated. Subjects received drug (dosing up to 2100 mg) with no side adverse effects reported. In particular, 47 subjects received single-dose from 2.1 to 2100 mg and 24 subjects received 14 day multiple doses from 50 mg to 1800 mg. All doses were well tolerated, with no significant side effects including blood pressure. Pharmacokinetics of orally administered capsules was consistent with once-daily dosing. (http://oreholdings.com/wp-content/uploads/2013/06/09.10.09-425.pdf). 300 mg (active drug) oral capsules were used in a Phase Ib/IIa clinical trial that was, however, abandoned. (https://clinicaltrials.gov/ct2/show/NCT01039597)."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T1","span":{"begin":140,"end":153},"obj":"http://purl.obolibrary.org/obo/GO_0006954"}],"text":"In humans ORE1001/GL1001/MLN-4760 was already proposed and tested in clinical trials. Its pharmaceutical indication was for digestive tract inflammations (Inflammatory bowel disease, gastritis and colitis) that are correlated with overexpression of ACE2. In a Phase I clinical testing up 14 days dosing, ORE1001 was well tolerated. Subjects received drug (dosing up to 2100 mg) with no side adverse effects reported. In particular, 47 subjects received single-dose from 2.1 to 2100 mg and 24 subjects received 14 day multiple doses from 50 mg to 1800 mg. All doses were well tolerated, with no significant side effects including blood pressure. Pharmacokinetics of orally administered capsules was consistent with once-daily dosing. (http://oreholdings.com/wp-content/uploads/2013/06/09.10.09-425.pdf). 300 mg (active drug) oral capsules were used in a Phase Ib/IIa clinical trial that was, however, abandoned. (https://clinicaltrials.gov/ct2/show/NCT01039597)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T484","span":{"begin":86,"end":254},"obj":"Sentence"},{"id":"T485","span":{"begin":255,"end":331},"obj":"Sentence"},{"id":"T486","span":{"begin":332,"end":416},"obj":"Sentence"},{"id":"T487","span":{"begin":417,"end":554},"obj":"Sentence"},{"id":"T488","span":{"begin":555,"end":644},"obj":"Sentence"},{"id":"T489","span":{"begin":645,"end":802},"obj":"Sentence"},{"id":"T490","span":{"begin":803,"end":961},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"In humans ORE1001/GL1001/MLN-4760 was already proposed and tested in clinical trials. Its pharmaceutical indication was for digestive tract inflammations (Inflammatory bowel disease, gastritis and colitis) that are correlated with overexpression of ACE2. In a Phase I clinical testing up 14 days dosing, ORE1001 was well tolerated. Subjects received drug (dosing up to 2100 mg) with no side adverse effects reported. In particular, 47 subjects received single-dose from 2.1 to 2100 mg and 24 subjects received 14 day multiple doses from 50 mg to 1800 mg. All doses were well tolerated, with no significant side effects including blood pressure. Pharmacokinetics of orally administered capsules was consistent with once-daily dosing. (http://oreholdings.com/wp-content/uploads/2013/06/09.10.09-425.pdf). 300 mg (active drug) oral capsules were used in a Phase Ib/IIa clinical trial that was, however, abandoned. (https://clinicaltrials.gov/ct2/show/NCT01039597)."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T162","span":{"begin":155,"end":181},"obj":"Phenotype"},{"id":"T163","span":{"begin":183,"end":192},"obj":"Phenotype"},{"id":"T164","span":{"begin":197,"end":204},"obj":"Phenotype"}],"attributes":[{"id":"A162","pred":"hp_id","subj":"T162","obj":"http://purl.obolibrary.org/obo/HP_0002037"},{"id":"A163","pred":"hp_id","subj":"T163","obj":"http://purl.obolibrary.org/obo/HP_0005263"},{"id":"A164","pred":"hp_id","subj":"T164","obj":"http://purl.obolibrary.org/obo/HP_0002583"}],"text":"In humans ORE1001/GL1001/MLN-4760 was already proposed and tested in clinical trials. Its pharmaceutical indication was for digestive tract inflammations (Inflammatory bowel disease, gastritis and colitis) that are correlated with overexpression of ACE2. In a Phase I clinical testing up 14 days dosing, ORE1001 was well tolerated. Subjects received drug (dosing up to 2100 mg) with no side adverse effects reported. In particular, 47 subjects received single-dose from 2.1 to 2100 mg and 24 subjects received 14 day multiple doses from 50 mg to 1800 mg. All doses were well tolerated, with no significant side effects including blood pressure. Pharmacokinetics of orally administered capsules was consistent with once-daily dosing. (http://oreholdings.com/wp-content/uploads/2013/06/09.10.09-425.pdf). 300 mg (active drug) oral capsules were used in a Phase Ib/IIa clinical trial that was, however, abandoned. (https://clinicaltrials.gov/ct2/show/NCT01039597)."}